Multiple Myeloma

Latest News

Latest Videos

Amrita Y. Krishnan, MD, and Binod Dhakal, MD

MajesTEC-1: Efficacy and Safety of Teclistamab

The Current Treatment Landscape for Relapsed/Refractory Multiple Myeloma

A panel of 4 experts on multiple myeloma

Exciting Developments in Relapsed/Refractory Multiple Myeloma

Triaging and Prioritizing Patients with Multiple Myeloma

CAR T-Cell Therapy: Leukapheresis Practices

Patient Profile 2: Managing ICANS Following CAR T-Cell Therapy

Strategies to Manage or Mitigate CRS

Treatment Considerations and the Role of BCMA-Targeting CAR T in MM

Patient Profile: A 60-Year-Old with Stage III KLC MM

Underlying Mechanisms and Signs of CRS

CME Content

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Iowa Oncology Society

Marla D. Lipsyc-Sharf, MD; Sheila Donnelly, MD

Video

Show Me the Data™: Post-TKI Sequencing in EGFR-Mutated NSCLC—Optimizing Current Strategies and Preparing for New Treatment Modalities

Christine M. Lovly, MD, PhD, FASCO; Xiuning Le, MD, PhD; Hossein Borghaei, DO, MS; Lyudmila Bazhenova, MD

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Texas Society of Clinical Oncology

Marla D. Lipsyc-Sharf, MD; Parth Khade, MD

Video

22nd Annual International Symposium on Melanoma and Other Cutaneous Malignancies®

Omid Hamid, MD; Sapna Patel, MD

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | North Carolina Oncology Association

Marla D. Lipsyc-Sharf, MD; Yan Ji, MD

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | New Mexico Society of Clinical Oncology

Marla D. Lipsyc-Sharf, MD; Kimberly Ku, MD

Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Ghassan Abou-Alfa, MD, MBA

Multimedia

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

Hope S. Rugo, MD, FASCO; Neil M. Iyengar, MD; Komal Jhaveri, MD, FACP

Multimedia

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Rebecca Shatsky, MD; Kelly McCann, MD, PhD; Michelle L. Taylor, ANP-BC

Video

From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Shubham Pant, MD, MBBS

Video

Proactive Adverse Event Management for HER2+ BTC Treatments

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Rachna T. Shroff, MD, MS, FASCO

Multimedia

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

Yana G. Najjar, MD; Douglas B. Johnson, MD, MSCI; Rahul A. Sheth, MD, FSIR

Video

A Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)

Cindy Neunert, MD, MSCS; Hanny Al-Samkari, MD; Joseph Shatzel, MD, MCR

Video

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

William J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhD

Video

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

Jonathan W. Goldman, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhD

Video

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

Video

GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

John H. Strickler, MD; Stacey A. Cohen, MD; Aparna Parikh, MD; Kanwal P.S. Raghav, MBBS, MD

Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Eileen M. O’Reilly, MD; E. Gabriela Chiorean, MD, FASCO; Michael J. Pishvaian, MD, PhD; Brian Wolpin, MD, MPH

Video

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Gail J. Roboz, MD; Hagop Kantarjian, MD; Catherine Lai, MD, MPH; Amer Zeidan, MBBS, MHS

Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Balazs Halmos, MD, MS; Enriqueta Felip, MD, PhD; Julia Rotow, MD

Video

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Rami Komrokji, MD; Gabriela Hobbs, MD; John Mascarenhas, MD; Naveen Pemmaraju, MD

Multimedia

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD

Multimedia

Breaking Down the Rationale for Targeting TROP2 in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Audio

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Hossein Borghaei, DO, MS

Video

Cross-Disease Integration of Immunotherapy Innovations

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

Video

Optimizing Treatment for Biliary Tract Cancers

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

Multimedia

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc; Filipa Lynce, MD; Rita Nanda, MD; Tiffany A. Traina, MD, FASCO

Video

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Ana C. Garrido-Castro, MD; Pedram Razavi, MD, PhD

Multimedia

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Video

(CME Track) Live Tumor Board: Squamous Cell Carcinoma of the Head & Neck - Post-CRT Decisions in the Locally Advanced Setting

Quynh-Thu Le, MD, FACR, FASTRO; Vlad C. Sandulache, MD, PhD

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Rocky Mountain Oncology Society

Seth A. Wander, MD, PhD; Kara M. Schenk, MD

Virtual Event

Oncology Town Hall - Translating the Latest Updates Into the Care of Patients With AML in Community Practices

April 9, 2026

In-Person + Virtual Event

11th Annual School of Gastrointestinal Oncology® (SOGO®)

April 11, 2026

In-Person + Virtual Event

Tumor Board: Clinical Integration of Molecular Profiling in Glioma - Transforming the Use of Targeted Therapy

April 20, 2026

Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Rebecca Heist, MD, MPH; Alex A. Adjei, MD, PhD, FACP; Sandip Patel, MD, FASCO; Jeremy Segal, MD, PhD

Video

Medical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted Therapies

Vinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA; Stephen J. Bagley, MD, MSCE; Angela Waanders, MD, MPH, MS

$Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma$

Video

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

Video

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Joyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCO

Multimedia

Establishing the Rationale for ADC and ICI Combinations in TNBC

Virginia Kaklamani, MD, DSc; Tiffany A. Traina, MD, FASCO

Multimedia

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc

Multimedia

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Video

Broadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular Carcinoma

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

Audio

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Misty D. Shields, MD, PhD

Multimedia

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Tiffany A. Traina, MD, FASCO

Audio

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Giannis Mountzios ΜD, PhD

Video

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Multimedia

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Imaging Matters: Decoding PSMA PET for Better Decision-Making

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

More News

MM: Influence of CAR T-Cell Therapy on Clinical Care

ByPeter Voorhees, MD,Kwabena Osei-Boateng, MD,Amy Soni, MD,Reed Friend, MD

September 27th 2023

The panel discusses how the emergence of CAR T-cell therapy has changed clinical care for patients with multiple myeloma.

Findings from the phase 2 GMMG-CONCEPT trial suggest that elevated lactate dehydrogenase levels correlated with worse survival in patients with newly diagnosed, high-risk multiple myeloma.

Isatuximab Combo Yields High MRD Negativity in High-Risk Multiple Myeloma

ByChris Ryan

September 27th 2023

Findings from the phase 2 GMMG-CONCEPT trial suggest that elevated lactate dehydrogenase levels correlated with worse survival in patients with newly diagnosed, high-risk multiple myeloma.

Toxicity Management in Patients With Multiple Myeloma

ByMichael Rosenzweig, MD, MS,Ashwin Kashyap, MD,Neel Talwar, MD,Natasha Garg, DO, MS

September 27th 2023

Experts explain strategies for toxicity management in patients receiving treatment for multiple myeloma, including monitoring risk of CRS.

Choosing Between Bispecific or CAR T-Cell Therapy for Patients With Multiple Myeloma

ByMichael Rosenzweig, MD, MS,Ashwin Kashyap, MD,Neel Talwar, MD,Natasha Garg, DO, MS

September 27th 2023

Shared insight on the factors to consider when choosing between a bispecific therapy and CAR T-cell therapy for a patient with multiple myeloma.

Cross Q&A: Exploring the Role of Ixazomib in Relapsed/Refractory Multiple Myeloma

ByVivian G. Oehler, MD,Andrew J. Cowan, MD,Rahul Banerjee, MD, FACP,Paul B. Koller, MD,Lawrence W. Liu, MD,Murali Janakiram, MD, MS

September 26th 2023

Key insights on real-world applications of the REMIX study, which evaluated real-world effectiveness and tolerability of the ixazomib-based regimen in relapsed/refractory multiple myeloma.

REMIX Study: Ixa-Len-Dex for Relapsed/Refractory Myeloma

ByVivian G. Oehler, MD,Andrew J. Cowan, MD,Rahul Banerjee, MD, FACP,Paul B. Koller, MD,Lawrence W. Liu, MD,Murali Janakiram, MD, MS

September 26th 2023

Outcomes of the REMIX study investigating the effectiveness and tolerability of ixa-len-dex in real-world relapsed/refractory myeloma patients, exploring progression-free survival, overall response rate, and safety.

CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

ByPeter Voorhees, MD,Kwabena Osei-Boateng, MD,Amy Soni, MD,Reed Friend, MD

September 20th 2023

A comprehensive overview of emerging data from the KarMMa-3 and CARTITUDE-4 studies on CAR T-cell therapy in relapsed/refractory multiple myeloma.

Multiple Myeloma: Treating Patients Who Have Relapsed Multiple Times

ByPeter Voorhees, MD,Kwabena Osei-Boateng, MD,Amy Soni, MD,Reed Friend, MD

September 20th 2023

A panel of experts discuss treatment and CAR T-cell therapy options for patients with relapsed/refractory disease who have limited treatment choices.

Clinical Scenario: A 61-Year-Old Woman With Relapsed/Refractory Multiple Myeloma (R/R MM)

ByMichael Rosenzweig, MD, MS,Ashwin Kashyap, MD,Neel Talwar, MD,Natasha Garg, DO, MS

September 20th 2023

Michael Rosenzweig, MD, MS, presents the clinical scenario of a 61-year-old woman with relapsed/refractory multiple myeloma for panel discussion.

Bone Disease Prophylaxis in Patients With Transplant-Eligible NDMM

ByMichael Rosenzweig, MD, MS,Ashwin Kashyap, MD,Neel Talwar, MD,Natasha Garg, DO, MS

September 20th 2023

Expert panelists discuss the options for preventing bone disease in patients with multiple myeloma, including osteonecrosis of the jaw.

Cross Q&A: Balancing Progression and Lines of Therapy at Myeloma Relapse

ByVivian G. Oehler, MD,Andrew J. Cowan, MD,Rahul Banerjee, MD, FACP,Paul B. Koller, MD,Lawrence W. Liu, MD,Murali Janakiram, MD, MS

September 19th 2023

Expert insights into tailoring treatment for biochemical relapse in multiple myeloma patients, considering disease progression and the impact of various therapy lines on treatment decisions.

Cross Q&A: Navigating Biochemical Relapse and MRD Resurgence in Multiple Myeloma

ByVivian G. Oehler, MD,Andrew J. Cowan, MD,Rahul Banerjee, MD, FACP,Paul B. Koller, MD,Lawrence W. Liu, MD,Murali Janakiram, MD, MS

September 19th 2023

An insightful discussion among specialists about the challenges of treating biochemical relapse and MRD resurgence in multiple myeloma patients, exploring nuanced considerations, patient collaboration, and the evolving landscape of treatment strategies.

Assessing Cytokine Release Syndrome After Treatment With Teclistamab in Multiple Myeloma

ByONCOLOGY Staff

September 18th 2023

Thomas G. Martin, MD, discussed with his colleagues cytokine release syndrome after treatment with teclistamab for patients with multiple myeloma.

Teclistamab Reviewed as Potential Treatment Option in Relapsed/Refractory Multiple Myeloma

ByONCOLOGY Staff

September 15th 2023

CancerNetwork hosted a Training Academy focused on sequencing therapies for patients with multiple myeloma who are treated with bispecific antibodies.

The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.

August 2023 Snap Recap: Chemo Shortages, FDA Approvals in Multiple Myeloma

ByHayley Virgil

September 15th 2023

The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.

Assessing Frailty in Multiple Myeloma

ByPeter Voorhees, MD,Kwabena Osei-Boateng, MD,Amy Soni, MD,Reed Friend, MD

September 13th 2023

Expert perspectives on assessing frailty for patients with multiple myeloma and its effect on treatment decisions.

Treatment Strategies for Patients With Transplant-Ineligible MM

ByPeter Voorhees, MD,Kwabena Osei-Boateng, MD,Amy Soni, MD,Reed Friend, MD

September 13th 2023

Clinical insights on treatment options and strategies for patients with multiple myeloma who are not eligible for transplant.

Factors for Consideration When Treating Frail Patients With Transplant-Ineligible NDMM

ByMichael Rosenzweig, MD, MS,Ashwin Kashyap, MD,Neel Talwar, MD,Natasha Garg, DO, MS

September 13th 2023

Focused discussion on tailoring treatment decision-making for patients with multiple myeloma classified as frail.

Selecting Between DRd and VRd Combination Regimens for Patients With Transplant-Ineligible NDMM

ByMichael Rosenzweig, MD, MS,Ashwin Kashyap, MD,Neel Talwar, MD,Natasha Garg, DO, MS

September 13th 2023

A panel of experts explain how they select between the DRd (daratumumab, lenalidomide, dexamethasone) and VRd (bortezomib, lenalidomide, dexamethasone) treatment regimens for patients with transplant-ineligible newly diagnosed multiple myeloma.

Biochemical and Clinical Progression: The Two Faces of Relapsed MM

ByVivian G. Oehler, MD,Andrew J. Cowan, MD,Rahul Banerjee, MD, FACP,Paul B. Koller, MD,Lawrence W. Liu, MD,Murali Janakiram, MD, MS

September 12th 2023

Andrew Cowan, MD, discusses the complexities of relapsed multiple myeloma, distinguishing between biochemical and clinical progression, analyzing survival data, and raising questions about optimal treatment strategies.

Team Introductions: MM Experts From the Fred Hutchinson Cancer Center and City of Hope

ByAndrew J. Cowan, MD,Rahul Banerjee, MD, FACP,Vivian G. Oehler, MD,Paul B. Koller, MD,Lawrence W. Liu, MD,Murali Janakiram, MD, MS

September 12th 2023

An overview of the program agenda and introduction of expert panelists from the Fred Hutchinson Cancer Center and City of Hope teams.

A single dose of motixafortide results in achievement of stem cell collection goal in patients with multiple myeloma.

Motixafortide/Filgrastim OKed by FDA for Transplantation in Multiple Myeloma

ByHayley Virgil

September 11th 2023

A single dose of motixafortide results in achievement of stem cell collection goal in patients with multiple myeloma.

Bispecific antibodies may be more broadly applicable as treatment for patients with multiple myeloma in the short-term, according to Ajai Chari, MD.

Many Factors Influence Selection of CAR T Therapy, Bispecifics in Myeloma

ByKyle Doherty

September 11th 2023

Bispecific antibodies may be more broadly applicable as treatment for patients with multiple myeloma in the short-term, according to Ajai Chari, MD.

Patients with multiple myeloma and enduring MRD-negativity are able to achieve the deepest responses with ciltacabtagene autoleucel, according to Yi Lin, MD, PhD.

Cilta-Cel Yields PFS, Durable Responses in R/R Multiple Myeloma

BySilas Inman

September 9th 2023

Patients with multiple myeloma and enduring MRD-negativity are able to achieve the deepest responses with ciltacabtagene autoleucel, according to Yi Lin, MD, PhD.

Transplant and Treatment Decision-Making in Multiple Myeloma

ByPeter Voorhees, MD,Kwabena Osei-Boateng, MD,Amy Soni, MD,Reed Friend, MD

September 6th 2023

The expert panel discusses factors that influence referral to transplant as well as selecting maintenance and consolidation therapies for patients with multiple myeloma.